For patients with advanced-stage HCC, treatment with the immune checkpoint inhibitor atezolizumab (an anti-PD-L1 antibody) plus the angiogenesis inhibitor bevacizumab (an anti-VEGFA antibody) yielded better overall and progression-free survival outcomes than sorafenib as a single agent [10,11], representing a breakthrough in the management of HCC. This evidence concerns the gene CD274 and hepatocellular carcinoma.